Pharmacogenomic testing uses a patient’s genome to identify their response to a drug, forming a key part of personalized medicine. Hundreds of clinical pharmacogenomics (PGx) tests are currently available on the market in the United States. With so many tests available, how can you determine that a test is clinically and analytically valid and holds clinical utility?

In this webinar, our expert speaker will outline the ACCE Model Project Framework as a tool for evaluating pharmacogenomic tests, describing the key considerations to take into account when implementing these tests. You’ll learn how to select the genetic variants to be tested, choose the appropriate genotyping technology and develop laboratory procedures for sample processing and data analysis.

Learning Objectives

• Explain the ACCE Model Project Framework for evaluating genetic tests, specific to PGx tests
• Define analytical and clinical validity and clinical utility and their importance to pharmacogenetic testing stakeholders
• Discuss key considerations laboratorians need to ponder when implementing a PGx test that meets ACCE standards